Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
Planetpaprika
Planetpaprika Feb. 3 at 1:57 PM
$ABUS the bearish interpretation... Estoppel narrows Arbutus’s argument, making literal infringement harder to prove. No doctrine of equivalents means a tighter range of patent coverage. the bullish interpretation :-) Patents remain in the case and are jury questions on validity and literal infringement. Delaware trial is not dismissed or sent away under §1498, meaning Moderna is directly liable if found infringing. A jury verdict of validity + infringement could drive significant damages or force a settlement...
0 · Reply
BRTO
BRTO Feb. 3 at 1:47 PM
$ABUS suggest the pro-Arbutus crowd read this document in its entirety, especially the content beginning from about page 22 to the end. Although the first page tries to make light of the case and seem to be damning to Moderna, you’ll find in the body of the document explains ABUS’s case has some (major) dents in it regarding the molar ratio and direct infringement. I’ll reread it again, but my first impression is that this document contain facts and perspectives that are setbacks for ABUS and its investors, not a resounding win. Credit to Planetpaprika for posting.
1 · Reply
Planetpaprika
Planetpaprika Feb. 3 at 1:32 PM
$ABUS "It's also worth noting that Arbutus managed to end the quarter with roughly $93.7 million in cash, cash equivalents, and marketable securities. Now, if we take that operational spend of about $9.2 million as a proxy for cash burn and include it in the roughly $45.9 million over the first nine months of 2025 as a proxy for cash burn, Arbutus seems to have an estimated cash runway of about 1.5 years..." https://seekingalpha.com/article/4865237-arbutus-biopharma-stock-lnp-litigation-imdusiran-drive-near-term-catalysts
1 · Reply
SpaceCityKid
SpaceCityKid Feb. 3 at 12:37 PM
$ABUS "Check"... Your move Bancel.
0 · Reply
Planetpaprika
Planetpaprika Feb. 3 at 12:36 PM
$ABUS Delaware Court Memorandum... In Star Trek, members of Starfleet must observe the Prime Directive, even as they jump into or come out of warp speed. In this case, Arbutus Biopharma Corp. and Genevant Sciences GmbH (collectively, “Arbutus”) claim that... https://www.ded.uscourts.gov/sites/ded/files/opinions/22-252_1.pdf
0 · Reply
Thecheese12
Thecheese12 Feb. 3 at 12:22 PM
$ABUS Whats the best part is when all these people sit down in court and sing like a bird. 🐦. Under oath. 😅.
0 · Reply
Heavey
Heavey Feb. 3 at 9:25 AM
$ABUS gotta love this https://news.bloomberglaw.com/pharma-and-life-sciences/moderna-again-fails-to-shift-most-covid-shot-patent-costs-to-us
0 · Reply
Shortsales
Shortsales Feb. 3 at 8:40 AM
$ABUS
0 · Reply
Blueviking
Blueviking Feb. 3 at 6:06 AM
$ABUS https://investor.arbutusbio.com/node/19431/html
0 · Reply
jrothman22
jrothman22 Feb. 3 at 4:48 AM
$ABUS 😎
1 · Reply
Latest News on ABUS
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Feb 3, 2026, 7:48 AM EST - 1 hour ago

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 2 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 6 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 7 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 9 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 9 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 10 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 11 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 11 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Jan 30, 2025, 3:40 PM EST - 1 year ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jan 7, 2025, 7:56 AM EST - 1 year ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:05 PM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Planetpaprika
Planetpaprika Feb. 3 at 1:57 PM
$ABUS the bearish interpretation... Estoppel narrows Arbutus’s argument, making literal infringement harder to prove. No doctrine of equivalents means a tighter range of patent coverage. the bullish interpretation :-) Patents remain in the case and are jury questions on validity and literal infringement. Delaware trial is not dismissed or sent away under §1498, meaning Moderna is directly liable if found infringing. A jury verdict of validity + infringement could drive significant damages or force a settlement...
0 · Reply
BRTO
BRTO Feb. 3 at 1:47 PM
$ABUS suggest the pro-Arbutus crowd read this document in its entirety, especially the content beginning from about page 22 to the end. Although the first page tries to make light of the case and seem to be damning to Moderna, you’ll find in the body of the document explains ABUS’s case has some (major) dents in it regarding the molar ratio and direct infringement. I’ll reread it again, but my first impression is that this document contain facts and perspectives that are setbacks for ABUS and its investors, not a resounding win. Credit to Planetpaprika for posting.
1 · Reply
Planetpaprika
Planetpaprika Feb. 3 at 1:32 PM
$ABUS "It's also worth noting that Arbutus managed to end the quarter with roughly $93.7 million in cash, cash equivalents, and marketable securities. Now, if we take that operational spend of about $9.2 million as a proxy for cash burn and include it in the roughly $45.9 million over the first nine months of 2025 as a proxy for cash burn, Arbutus seems to have an estimated cash runway of about 1.5 years..." https://seekingalpha.com/article/4865237-arbutus-biopharma-stock-lnp-litigation-imdusiran-drive-near-term-catalysts
1 · Reply
SpaceCityKid
SpaceCityKid Feb. 3 at 12:37 PM
$ABUS "Check"... Your move Bancel.
0 · Reply
Planetpaprika
Planetpaprika Feb. 3 at 12:36 PM
$ABUS Delaware Court Memorandum... In Star Trek, members of Starfleet must observe the Prime Directive, even as they jump into or come out of warp speed. In this case, Arbutus Biopharma Corp. and Genevant Sciences GmbH (collectively, “Arbutus”) claim that... https://www.ded.uscourts.gov/sites/ded/files/opinions/22-252_1.pdf
0 · Reply
Thecheese12
Thecheese12 Feb. 3 at 12:22 PM
$ABUS Whats the best part is when all these people sit down in court and sing like a bird. 🐦. Under oath. 😅.
0 · Reply
Heavey
Heavey Feb. 3 at 9:25 AM
$ABUS gotta love this https://news.bloomberglaw.com/pharma-and-life-sciences/moderna-again-fails-to-shift-most-covid-shot-patent-costs-to-us
0 · Reply
Shortsales
Shortsales Feb. 3 at 8:40 AM
$ABUS
0 · Reply
Blueviking
Blueviking Feb. 3 at 6:06 AM
$ABUS https://investor.arbutusbio.com/node/19431/html
0 · Reply
jrothman22
jrothman22 Feb. 3 at 4:48 AM
$ABUS 😎
1 · Reply
jrothman22
jrothman22 Feb. 3 at 4:40 AM
$ABUS I asked Jack my questions. Hopefully get a reply soon.
0 · Reply
Catalystinvestor
Catalystinvestor Feb. 3 at 4:05 AM
$ABUS
1 · Reply
hman62
hman62 Feb. 3 at 3:30 AM
$ABUS aged well. and stock options issued before year end ER. goodness. it sure looked like ATM was going to keep price down. now it flys.
1 · Reply
StockosaurusTex
StockosaurusTex Feb. 3 at 12:50 AM
$ABUS
0 · Reply
StockosaurusTex
StockosaurusTex Feb. 3 at 12:49 AM
$ABUS let’s go to trial.
0 · Reply
DocPharm
DocPharm Feb. 3 at 12:39 AM
$ABUS $ABUS also remember the Canadian government banned Moderna from using ABUS/$ROIV /GENEVANT LNP, except for 4 indications … sars-covid was not one Fact: Moderna used the LNP in their phase 1 study - to the T Fact: Moderna used a black box on their phase 2 and 3 protocols - “It’s proprietary, trust me” “fib a little” Fact: Moderna tried invalidating all of our patents;most survived Fact: Moderna had a defense of , the government made “us” do it. Now they don’t.
3 · Reply
DocPharm
DocPharm Feb. 3 at 12:09 AM
$ABUS jus remember Feb 25th last year “Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She is currently special counsel at Genevant with responsibilities including LNP litigation.”
0 · Reply
Jdvm
Jdvm Feb. 2 at 11:53 PM
$ABUS i'm gonna go out on a limb and say that Stéphane Bancel is having a bad evening.🤣🤣🤣🤣🤣
1 · Reply
jrothman22
jrothman22 Feb. 2 at 11:40 PM
$ABUS It’s like saying RC Cola infringes on Coca Cola bc they both use carmel dye, water and sugar. That’s standard.
0 · Reply
Mibl
Mibl Feb. 2 at 11:19 PM
$MRNA $ABUS Imho this is a win win for both if there is a buyout before the jury. $ABUS Will pop on the premium and Moderna might fall initially but the overhead is now gone. Going to court, I think anything can happen. If it was black and white like this, why would Moderna waste time for a "guilty" verdict. Imo seems like a good way to hedge here is to invest in both companies lol win win situation. Added $ABUS and will continue to add until verdict. Already long moderna since $23ISH. Good luck everyone, let's make some money!
3 · Reply
invest5555
invest5555 Feb. 2 at 10:38 PM
$ABUS great!
0 · Reply
Jdvm
Jdvm Feb. 2 at 10:22 PM
$ABUS . The "50:10:38.5:1.5" Smoking Gun ​Publicly available scientific papers (which Moderna’s own scientists co-authored) already disclose that their vaccine uses a lipid ratio of 50:10:38.5:1.5. It just keeps getting better.
1 · Reply